Tumor suppressors in acute myeloid leukemia

Leuk Lymphoma. 2021 Oct;62(10):2320-2330. doi: 10.1080/10428194.2021.1907372. Epub 2021 Apr 30.

Abstract

Acute myeloid leukemia (AML) is a very heterogeneous type of blood cancer, which presents with a high rate of mortality especially in elderly patients. Better understanding of critical players, such as molecules with tumor suppressive properties, may help to fine-tune disease classification and thereby treatment modalities for this detrimental disease. Here, we summarize well-known and established tumor suppressors as well as emerging tumor suppressors, including transcription factors (TCFs) and other transcriptional regulators, such as epigenetic modulators. In addition, we look into the versatile field of miRNAs also interfering with tumorigenesis and progression, which offer new possibilities in AML diagnosis, prognosis, and therapy.

Keywords: Acute myeloid leukemia; epigenetic regulator; miRNA; transcription factor; tumor suppressor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Carcinogenesis
  • Cell Transformation, Neoplastic
  • Humans
  • Leukemia, Myeloid, Acute* / diagnosis
  • Leukemia, Myeloid, Acute* / genetics
  • Leukemia, Myeloid, Acute* / therapy
  • MicroRNAs* / genetics
  • Prognosis

Substances

  • MicroRNAs